Butterfly Network vs Nabla

By valuation, Butterfly Network is the larger company at $957M versus $180M — a 5.3x difference. Size can also be measured by team: Butterfly Network employs 500-1000 people while Nabla has 80 employees.

Butterfly Network has raised more in total funding at $370M, compared to Nabla's $131M — a gap of $239M. Combined, the two companies have completed 6 known funding rounds.

Butterfly Network leads with an Awaira Score of 85/100, while Nabla sits at 73/100. That 12-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Butterfly Network was founded by John Martin in 2011. Nabla was founded by Alexandre Lebrun in 2018. Visit each company's profile on Awaira for a full founder biography.

Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Butterfly Network operates in the AI Healthcare sector and is headquartered in United States. Founded in 2011 by John Martin, Butterfly Network has raised $370M in total funding, achieving a valuation of $957M as of its latest round. The company's funding journey includes a Seed of $11.1M in 2011, a Series A of $29.6M in 2012, a Series B of $66.6M in 2014, a Series C of $114.7M in 2015, a Series D of $148M in 2016. With approximately 500-1000 employees, Butterfly Network has established itself as a Public-stage player in the AI Healthcare market. The company holds an Awaira Score of 85/100, reflecting its strong position across valuation, funding trajectory, team scale, and market influence. Butterfly Network competes in a rapidly evolving segment alongside other AI Healthcare companies. Based in United States, Butterfly Network is part of a growing international AI ecosystem attracting talent and investment. The AI Healthcare space has attracted significant investment in recent years, with companies racing to capture enterprise and consumer demand for AI-powered solutions. Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform applies natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency.

Butterfly Network got there first, launching in 2011 — that's 7 years of extra runway. Nabla didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Butterfly Network has about 500-1000 employees; Nabla has about 80. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Butterfly Network and Nabla compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.